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a b s t r a c t
Objective: To analyze themisoprostol use in pregnancieswith intrauterine fetal death (IUFD),
considering mode of delivery and induction-delivery interval.
Methods: Descriptive study including 171 pregnant women with IUFD, in the second or
third trimester, submitted to labor induction with vaginal misoprostol and/or induc-
tion/augmentation with intravenous oxytocin, from 2005 to 2008, at a teaching-hospital
of the Brazilian Uniﬁed Health System (Sistema Único de Saúde - SUS).
Results: Misoprostol alone (treatment A), misoprostol plus oxytocin (treatment B), and
oxytocin alone (treatment C) were administered in 9.3%, 19.9%, and 70.8% of the cases,
respectively. One-third of pregnancies were less than 28 weeks, and 2.9% required a cae-
sarean section. The percentage of vaginal delivery in treatments A and B combined (98.0%)
was similar to treatment C (96.7%). The mean induction-delivery interval was 15.4hours.
Comparing multiple groups, the mean induction-delivery interval was signiﬁcantly shorter
in treatment A (20.1hours) than in treatment B (33.3hours), and was longer than in
treatment C (9.7hours). The majority (71%) of cases required a single administration of
misoprostol, and the total dosage was lower in treatment A (mean: 98.4g) compared with
treatment B (mean: 157.0g).
Conclusion: Misoprostol effectively contributed to delivery of IUFD by vaginal route assisted
under routine conditions of a public health service in Brazil, demonstrating its importance
in cases resistant to usual induction methods, and its availability in Brazilian public health
services is recommended.
© 2013 Elsevier Editora Ltda.
Uso de misoprostol na rotina para terminar gestac¸ões com feto morto
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Objetivo: Descrever o uso de misoprostol em gestac¸ões com óbito fetal intraútero, con-
siderando o tipo de parto e o intervalo induc¸ão-parto.
 Study conducted at the Obstetrics Department of Hospital Geral de Nova Iguac¸u, Nova Iguac¸u, RJ, Brazil.
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Ocitocina
Trabalho de parto induzido
Parto obstétrico
Óbito fetal
Feto morto
Métodos: Estudo descritivo de 171 gestantes com óbito fetal intraútero, no segundo ou ter-
ceiro trimestres, submetidas à induc¸ão do parto com misoprostol vaginal ou acelerac¸ão do
parto com ocitocina parenteral, de 2005 a 2008 em um hospital-escola do Sistema Único de
Saúde (SUS) do Brasil.
Resultados: Misoprostol isolado (tratamento A), misoprostol complementado pela ocitocina
(tratamento B) e ocitocina isolada (tratamento C) foram administrados em 9,3%, 19,9%
e 70,8% dos casos, respectivamente. Um terc¸o das gestac¸ões estavam com menos de 28
semanas e 2,9% delas requereram operac¸ão cesariana. O percentual de parto vaginal nos
tratamentos A e B combinados (98,0%) foi similar ao tratamento C (96,7%). A média do inter-
valo induc¸ão-parto foi menor no tratamento A (20,15 horas; DP=15,8 horas) comparado ao
tratamento B (33,31 horas; DP=29,6 horas) e a proporc¸ão de partos pela via vaginal ocorridos
dentro de 48 horas foi de 100% (tratamento A), 96,7% (tratamento B) e 96,7% (tratamento C).
A maioria dos casos (71%) tratados com misoprostol requereu uma única administrac¸ão da
droga e a média da dosagem total foi menor no tratamento A (média 98,4g) comparado ao
tratamento B (média: 157,0g).
Conclusão: Misoprostol efetivamente contribuiu para a resoluc¸ão de gestac¸ões com óbito
fetal intraútero, mostrando a importância de sua aplicac¸ão em casos resistentes aos méto-
dos usuais de induc¸ão e de sua disponibilizac¸ão nos servic¸os públicos de saúde no Brasil.
© 2013 Elsevier Editora Ltda.
Introduction
The effectiveness of misoprostol for labor induction has been
widely demonstrated by several randomized controlled trials
(RCTs),1 but the absence of its registration for obstetrical and
gynecological applications remains an important problem in
most countries.2 Currently, Brazil and Peru are the only Latin-
American countries to make misoprostol ofﬁcially licensed
for reproductive health indications. In Brazil, misoprostol is
approved for vaginal use, and the preparation is indicated in
caseswhen it is necessary to induce labor in a full-termor near
full-term pregnancy, to induce labor of retained dead fetus, or
in the case of legal abortions.3
Despite ofﬁcial regulation by government, the irregular
supply of misoprostol is still a barrier in Brazil, which might
limit its access4 and in turn lead health professionals to make
difﬁcult choices regarding the treatments to be administered
and/or opt for a suboptimal amount of misoprostol.5 Addi-
tionally, the use of misoprostol in the presence of a previous
uterine scar6 and/or previous caesarean section increases the
risk of uterine rupture.7
As the lack of license for certain misoprostol obstetrical
indications is not a problem in Brazil, experiences other than
RCT may contribute to increase the understanding of the
subject, especially if the focus is on medical labor induction
practiced in low-resource environments. Thus, the objective of
this study was to describe the use of misoprostol in pregnan-
cies with intrauterine fetal death (IUFD), in the second or third
trimester, regarding mode of delivery and induction-delivery
interval.
Methods
This was a descriptive study carried out with pregnant women
with IUFD who were submitted to medical labor induction
from January of 2005 to December of 2008 at a teaching
hospital of the BrazilianUniﬁedHealth System (SistemaÚnico
de Saúde – SUS).
Study population
According to the Brazilian Mortality Information System,
410 singleton gestations with dead fetuses registered at
the aforementioned hospital were over 499 g birth weight
and/or ≥ 22 weeks of gestational age, and thus were eli-
gible for this study. Initially a total of 219 women were
excluded for the following reasons: postpartum admis-
sion (15), emergency C-section (98), spontaneous deliveries
(104), or use of Foley catheter followed by a C-section
(2). The inclusion criteria for medical labor induction
and/or augmentation with medications was fulﬁlled by
191 pregnant women. Of these, 20 were also excluded
for the following reasons: (i) eight cases of medical
induction in simultaneous use of Foley catheter method;
(ii) ten cases of clinical induction initiated when the
fetus was still alive (one anencephalic, one unexplained
death, and eight cases of chorioamnionitis); (iii) two
cases of loss of informationabout fetal vitality at the beginning
of induction. The current study comprised 171 patients who
received medical treatment for labor induction with vaginal
misoprostol or labor augmentation with intravenous oxytocin
infusion.
The medical treatment for labor induction or labor
augmentation to terminate IUFD pregnancies is routinely per-
formed in this hospital with misoprostol and/or oxytocin.
Misoprostol is indicated for unfavorable cervix considering
length, position, dilation, and station, and is exclusively
administered vaginally. A favorable or mature cervix is that
with 2 cm of dilation, 80%effaced, soft, and in midposition,
and with a fetal occiput at −1 station, with a prognosis of
vaginal delivery;8 otherwise, the cervix is classiﬁed as imma-
ture or unfavorable. When the cervix becomes favorable, the
intravenous oxytocin infusion is performed to supplement
previously administered misoprostol. In contrast, oxytocin
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alone is recommended for augmentation of spontaneously
initiated labor or to supplement the induction with misopros-
tol. The oxytocin infusion is administered in 500mL of 5%
glucose, intravenously, with initial dose of 2 mIU per minute,
increasing until the uterus attains a level of activity similar to
the physiological.
The mode of delivery (vaginal or caesarean section) and
the induction-delivery interval were the two main outcomes
studied. The induction-delivery interval comprises the inter-
val between the beginning of induction or augmentation with
use of medication and the fetus expulsion. This interval was
measured in hours, and evaluated both as continuous and cat-
egorical variables, based on two categories (≤ 48hours and >
48hours).
The following medical treatments were considered: miso-
prostol alone (treatment A), misoprostol supplemented with
oxytocin (treatment B), and oxytocin alone (treatment C).
Besides the mode of delivery and induction-delivery interval,
the total dose of misoprostol (in g), the number of misopros-
tol administrations, and complementation with postpartum
curettage were also analyzed.
The maternal/obstetric characteristics selected were
maternal age (< 20 years; 20 to 34 years; 35 and over); nulli-
parity (yes/no); gestational age (< 28/≥ 28 weeks); previous
caesarean section (yes/no); immature cervix (yes/no); and
intact amniotic membranes (yes/no).
Statistical analysis was performed using the statistical
package R. The continuous variables were expressed as mean
and standard deviation (SD), and categorical variables were
expressed as frequency and percentage.
This study follows the principles of the Declaration of
Helsinki, and was approved by the research ethics committee
of the teaching hospital under No. 21/2009.
Results
One hundred and seventy-one cases of IUFD gestations were
analyzed. Misoprostol was administered in 29.2% of the cases.
All administrations of misoprostol were performed by vagi-
nal route, 32% of which were misoprostol alone (treatment A),
and 68% of which were supplemented with intravenous oxy-
tocin (treatment B). Oxytocin alone (treatment C) was given
in 70.8% of cases. The means maternal age and gestational
age were 26.1 years (SD=7.6 years; range: 14 to 46 years) and
30.7weeks (SD=5.4weeks; range: 18 to 42weeks), respectively.
One-third of the pregnancies were less than 28 weeks, and
the mean birth weight was 1,707.2 g (SD=967.1 g; range: 465 to
5,760 g). All mothers in the misoprostol groups (treatment A or
treatment B), and 79.1% of those in the oxytocin group (treat-
ment C) had intact amniotic membranes. Unfavorable cervix
was the main maternal/obstetrical characteristic found in the
treatment A group (100.0%) and treatment B group (97.1%)
(Table 1).
The contribution for vaginal delivery of treatments A and
B combined was as high as treatment C (98.0% vs. 96.7%). C-
section occurred in one out of 34 mothers of the treatment
B group, and in four out of 121 mothers of the treatment C
group. The relationbetween the type of treatment andmodeof
delivery revealed that misoprostol alone and misoprostol sup-
plemented by oxytocin had a similar effect to that of oxytocin
alone (Table 2).
The majority (71%) of cases treated with misoprostol
required a single administration of the medication (range:
one to four administrations). Among the cases with a single
administration, 75.0% and 69.7% were from group A and group
B, respectively. Repeated administrations were performed
Table 1 – Maternal and obstetrical characteristics of 171 pregnancies with intrauterine fetal death, by type of labor
induction or labor augmentation
Variable Treatment A
Misoprostol alone
Yes (n=16)
n (%)
Treatment B
Misoprostol plus oxytocin
Yes (n=34)
n (%)
Treatment C
Oxytocin alone
Yes (n=121)
n (%)
Maternal age (years)
13-19 6 (37.5) 11 (32.3) 26 (21.5)
20-34 10 (62.5) 16 (47.1) 75 (62.0)
≥ 35 0 (0) 7 (20.6) 20 (16.5)
Nulliparity
Yes 7 (43.7) 17 (50.0) 44 (36.4)
No 9 (56.3) 17 (50.0) 77 (63.6)
Prior cesarean section* (n = 170)
Yes 3 (18.7) 6 (17.6) 18 (15.0)
No 13 (81.3) 28 (82.4) 102 (85.0)
Gestational age* (n = 167)
≤ 27 weeks 6 (37.5) 12 (35.3) 37 (31.6)
≥ 28 weeks 10 (62.5) 22 (64.7) 80 (68.4)
Cervix status* (n = 170)
Immature 16 (100.0) 33 (97.1) 57 (47.5)
Mature 0 (0) 1 (2.9) 63 (52.5)
∗ Results exclude women with incomplete data.
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Table 2 – Mode of delivery of 171 pregnancies with intrauterine fetal death, by type of treatment for labor induction
or labor augmentation
Type of treatment Type of delivery Total (n)
Vaginal (n=166)
n (%)
Cesarean section
(n=5)
n (%)
Misoprostol in separate categories
Treatment A (misoprostol alone) 16 (100.0) 0 (0) 16
Treatment B (misoprostol plus ocytocin) 33 (97.1) 1 (2.9) 34
Treatment C (Oxyciton) 117 (96.7) 4 (3.3) 121
Misoprostol in combined categories
Treatment A and treatment B combined 49 (98.0) 1 (2.0) 50
Treatment C (Oxyciton) 117 (96.7) 4 (3.3) 121
twice (6.2% vs. 18.1%), three times (12.5% vs. 6.1%), and four
times (6.2% vs. 6.1%) in group A and group B, respectively.
Total value of dosage varied between 25g to 400g in the
treatment A (mean: 98.4g; SD=92.8) and treatment B groups
(mean: 157.0g; SD=92.7).
Forty percent of the women who received treatment with
misoprostol underwent postpartum curettage. The procedure
was less common in the treatment A group (31.2%) than in the
treatment B group (44.1%). Overall, 62% of the patients with
less than 28 weeks of gestational age underwent this surgical
intervention.
The mean induction-delivery interval for the entire group
was 15.37hours (SD=19.4hours; range: 0.25 to 165hours).
Considering particular groups, the means were 20.15hours
(treatment A), 33.31hours (treatment B) and 9.70hours (treat-
ment C) (Table 3).
At the end of 48hours, 96% of the pregnancies were ter-
minated, the majority of them (95.8%) by vaginal route. The
proportions of cases treated with misoprostol alone, miso-
prostol plus oxytocin, and oxytocin alone who delivered
vaginallywithin 48hourswere 100%, 96.7%, and 96.7%, respec-
tively.
Discussion
Unlike ﬁndings based on RCTs conducted under ideal con-
ditions, the present results reﬂect the role of misoprostol in
obstetrics as practiced under the challenging conditions rou-
tinely faced in the public health services of the SUS. In these
circumstances, misoprostol helped to resolve more unfavor-
able clinical cases presenting cervical immaturity and intact
amniotic membrane, since the oxytocin group also included
pregnant women in advanced stages of cervical dilation. The
low number of induction failures and C-sections demon-
strated the importance of misoprostol in the resolution of
IUFD cases, in the second or third trimester, especially in low-
income settings.
Comparing with other studies,9–12 the present cases were
resolved with a relatively lower mean total dose of misopros-
tol and a single administration. Other studies13 report 400g
to 600g of the preparation to have been effective in achiev-
ing uterine evacuation within 24 to 48hours, and that lower
doses prolonged the induction-delivery interval. Despite the
prolonged induction-delivery interval observed in the present
study, the lower number of administrations may have reduced
the physical discomfort for a large number of these women,
already distressed by the fetal death, since they had to endure
only a single pelvic exam for the administration of vaginal
misoprostol.
The present study included women with one (19/27), two
(6/27), and three (2/27) prior C-sections (of any type), there-
fore having an increased risk for uterine rupture,7 although
this complicationdidnot occur. Careful patient selection, indi-
vidualization of doses administered, adequate monitoring of
induction-delivery interval, and especially, the few cases with
the combination of previous C-section and administration of
misoprostol may have contributed to such results. Accord-
ing to Ramirez et al.,14 3.4% of the women who had uterine
scarring and were submitted to medical labor induction for
the assisted delivery of a dead fetus experienced uterine rup-
ture in 19 American institutions. Although Ramirez et al.14
have emphasized that uterine rupture did not show associ-
ation with any drug employed, it is possible that it increases
maternal morbidity/mortality in this scenario.
Overall, the frequency of previous C-section was greater
than 15% considering all women, as well as in each treat-
ment group analyzed per se. Generally, with fetal death, there
Table 3 – Mean induction-delivery interval of 171 pregnancies with intrauterine fetal death, by type of treatment for labor
induction or labor augmentation.
Type of treatment n (%) Mean (hours) SD Minimum value Maximum value
Treatment A (misoprostol alone) 16 (9.3) 20.15 15.8 4 60
Treatment B (misoprostol plus oxytocin) 34 (19.9) 33.31 29.6 6 165
Treatment C (oxytocin alone) 121 (70.8) 9.70 11.6 0.25 75
SD, standard deviation.
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are reports in Brazil that a previous uterine scar reduces by
84% (OR 0.16; 95% CI: 0.04-0.71) the chance for drug-induced
labor,15 and increases by seven-fold (OR 7.0; 95% CI: 2.29-21.55)
the chance for a repeat C-section as the route to deliver the
dead fetus.16 In the present study, none of the cases requiring
a C-section was from the misoprostol alone group, as was also
observed by Aquino et al.10 However, one case with a previous
C-section submitted to treatment B resulted in induction fail-
ure. In the treatment C cases, the C-section was conducted to
guarantee the safety of the mother when the management of
labor was affected by prior multiple cesarean deliveries (one
case), systemic lupus erythematosus (one case), macrosomic
fetus weighting 5,760 g (one case), and placental abruption
associated with severe gestational hypertension (one case).
In the present study, postpartum curettagewasmuchmore
frequent when compared with C-sections, but similar to other
studies in proportion (40%).17 Itwasused to check for placental
residue retention, suspected by a clinical exam and/or imag-
ing. Although postpartum curettage was not the objective of
this study, it is important to highlight that early gestational
age appears to inﬂuence the need for the procedure,17 which
was performed in over 60% of the patients with gestational
age under 28 weeks.
As observed by others,18–21 in the present study the vast
majority of cases were delivered vaginally within 48hours;
however, the mean induction-delivery intervals were higher
in the misoprostol groups than in the oxytocin group, as was
found by Aquino et al.10 It probably occurred because the oxy-
tocin group had both women in situations which favored the
labor induction and women whose labor had spontaneously
started, and the labor was simply augmented by employing
the drug, which partially explains the mean interval found.
Also, lack of achievement of fetal expulsionwithin 48hours
did not extend to C-section, and four out of the seven more
prolonged cases were from the treatment B group; however,
misoprostol was applied according to the protocol in only
one of those four cases. According to Victora et al.,22 in the
standard clinical trial model, measures are taken for ensuring
ideal compliance, including intensively trained staff, strictly
controlled dosages, strong supervision, andmonitoring of side
effects. Such measures cannot be easily replicated under rou-
tine conditions. Despite the evidence, misoprostol was also
initiated after oxytocin (three cases), creating a group of much
worse prognosis (group B). The non-observance of the hospital
protocols and theunavailability of thedrugmayhavebeen rea-
sons for such conduct. However, these questions are beyond
the scope of the present study.
This study has limitations. Firstly, this was a retrospective
descriptive study, with data collection dependent on the com-
pleteness of medical forms, making it impossible to analyze
characteristics such as schooling and household income. This
issue did not appear to affect the study results, since all par-
ticipants were selected from a single public health service,
possibly reﬂecting the socioeconomic status of women that
attend SUS units in the region. Secondly, Bishop’s score infor-
mation was not available, so the option was made for using
cervix description (mature or immature) instead. Although
insufﬁcient to replace the aforementioned index, this char-
acteristic aided in the clinical classiﬁcation of the cases at
hand. Thirdly, it was not possible to classify some complaints
occasionally reported on the medical charts as side effects
of misoprostol, even though there are reports9 that vomiting,
nausea, fever, headache, and diarrhea are less common in the
vaginal route than in the oral route. Finally, the major issue
was the creationof the speciﬁc groups. Althoughuterus evacu-
ationwas themain goal in all groups, the cervix characteristics
were different. Unfortunately, the oxytocin group was com-
posed of women in advanced stages of cervical dilation, which
made comparison among the groups difﬁcult. The option was
to show the results employing a descriptive design.
As advantages, this study was performed at a government-
funded health service, which not only is a reference
maternity-hospital for high-risk pregnancies, but also receives
a wide variety of patients, and therefore better reﬂects the
assistential reality of the SUS, as well as the proﬁle of the
assisted population. Taking into account the focus on dead
fetus delivery, the size of the study population can be consid-
ered large.
Therefore, the induction of the delivery of dead fetuses
was successful, reinforcing the utilization of misoprostol in
government-provided healthcare services, and its ultimate
incorporation in the treatment of cases in which oxytocin has
not been successful. Nonetheless, its use must be carefully
evaluated, guidedbyevidence-basedprotocols, andmonitored
by professionals capable of managing any occurrence associ-
ated with the induction. In relation to other Latin-American
countries, the availability of misoprostol for vaginal admin-
istration in Brazil may be considered an advance. However,
additional concerns might result from situations such as: (i)
distribution restricted by law to hospitals,4 (ii) expensive com-
mercialization price, and (iii) product manufactured by only
one local pharmaceutical company.3 Such problems related
to the supply chain of misoprostol may constitute obstacles
for the renovation of the product’s license, which may in the
future result in the reduction of access to the medication
already guaranteed for some indications in the ﬁeld of repro-
ductive health in Brazil.
Conclusion
In conclusion, misoprostol effectively contributed to the
success of vaginal deliveries of dead fetuses, showing the
importance of its application to resolve the cases presenting
difﬁculty with the usual induction methods, and of its avail-
ability in public health services in Brazil.
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